Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Short term Debt (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Short term Debt for 4 consecutive years, with $797275.0 as the latest value for Q3 2025.

  • On a quarterly basis, Short term Debt rose 27.82% to $797275.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $797275.0, a 27.82% increase, with the full-year FY2024 number at $640830.0, down 72.22% from a year prior.
  • Short term Debt was $797275.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $776172.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $2.3 million in Q4 2023 to a low of $565949.0 in Q1 2024.
  • A 4-year average of $1.1 million and a median of $776172.0 in 2025 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: surged 176.48% in 2023, then plummeted 72.8% in 2024.
  • 60 Degrees Pharmaceuticals' Short term Debt stood at $834352.0 in 2022, then soared by 176.48% to $2.3 million in 2023, then tumbled by 72.22% to $640830.0 in 2024, then increased by 24.41% to $797275.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Short term Debt are $797275.0 (Q3 2025), $776172.0 (Q2 2025), and $635725.0 (Q1 2025).